WARD EU

Principal Investigator

Sharri Junadi Mortensen, MD, PhD student

Study design
Mixed-methods observational implementation study
Sample size
Four european countries including Denmark, The Netherlands, Portugal and Poland. Phase 1: 400 patients 120 nurses 100 patients and 30 nurses per country. Phase 2: 400 in-hospital patients, up to 200 home-monitored patients, up to 150 patients and 30 nurses per country
Study sites

Rigshospitalet, Bispebjerg Hospital, University Medical Centre Groningen, The Netherlands, NOVA Medical School, Portugal and Jagiellonian University Medical College, Poland

Inclusion criteria
  • Adults aged 18 years or older
  • Admitted with a medical or surgical condition
  • Expected hospital stay of at least two days
Study procedures
  • Informed consent
  • Observational data collection
  • Pre- and post-implementation questionnaires for patients and healthcare professionals
  • Patients wear clinical monitoring sensors
  • Nurses use WARD-CSS device/app for continuous vital-sign monitoring
  • Clinical outcomes and healthcare resource use are recorded
  • Follow-up up to 30 days after admission
Outcome
  • Phase 1:
    • Primary outcome: Map current monitoring practices
    • Secondary outcome: Patient experience
  • Phase 2:
    • Primary outcomes: Implementation potential and usability
    • Secondary outcomes: Adoption factors, data feasibility, complications ≤30 days
Trial registration
NCT07451249

–  Read more